Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum

Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.

Authors

Affiliations

¹ Department of Dermatology, University of Pisa, Pisa, Italy.
² Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, Pisa, Italy.
³ Division of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy.

PMID: 38597123
DOI: 10.1111/ajd.14266

No abstract available

Keywords: brodalumab; hidradenitis suppurativa; paradoxical reaction; psoriasis; pyoderma gangrenosum.

Publication types

Case Reports